Clinical trials: Genital Neoplasm, Female
Cervical Cancer, HPV Infection
Human Papilloma Virus (HPV) Self-collection and Women Adherence
Despite declining mortality in high-income countries, cervical cancer continues to be a public health problem in low and middle -income countries.
- Trial name
- NCT05059015
- Testing
- CERVICAL HPV, SELF SAMPLING HPV
- Where
- Colombia
- Volunteers
- 80 people
- Sponsor
- Instituto Nacional de Cancerologia, Columbia
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Polycystic Ovary Syndrome
Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women
RCT to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.
- Trial name
- NCT02910817
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Assiut University
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Endometrial Cancer
Revealing Engagement Patterns Among Endometrial Cancer Patients
The study intends to investigate the personal experiences of endometrial cancer patients who take part in a separate clinical study including a specific medication intervention.
- Trial name
- NCT05998798
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Cervical Cancer, Endometrial Cancer
Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.
An important part of staging and deciding the method of treatment is knowing areas of how cancer is involved. Diagnostic imaging is often used to determine the location of the cancer using techniques like nuclear medicine, MRI…
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer
- Trial name
- NCT03349463
- Testing
- Fluciclovine F18
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bital Savir-Baruch
Cervical Cancer, Locally Advanced Cervical Cancer
Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)
To date, the majority of clinical trials on checkpoint inhibitors have tested these agents as monotherapy, and the next logical step is to evaluate rational therapeutic associations.
- Trial name
- NiCOL (NCT03298893)
- Testing
- Nivolumab Injection, Cisplatin, radiotherapy
- Where
- 3 sites in France
- Volunteers
- 21 people
- Sponsor
- Institut Curie
Ovarian Cancer
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
The standard systemic treatment for ovarian cancer is platinum-based chemotherapy. However, majority of patients relapse and eventually progress to platinum resistance.
- Trial name
- NCT04908787
- Testing
- BD0801, Paclitaxel, Topotecan
- Where
- 55 sites in China
- Volunteers
- 421 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Ovarian Neoplasms
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
To evaluate and to compare the effectiveness of CA-125 and HE4 serum levels in epithelial ovarian cancer (OC) in follow-up in terms of time to detection of elevation after the end of the first line treatment.
- Trial name
- NCT02687321
- Testing
- Determination of CA 125 and HE4, Computed tomography
- Where
- 20 sites in Czechia, Hungary and 4 more
- Volunteers
- 150 people
- Sponsor
- Brno University Hospital
Ovarian Cancer
Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian cancer.
- Trial name
- MITO28MaNGOov4 (NCT03410784)
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 13 sites in Italy
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute, Naples
Endometrial Carcinoma, P53 Mutation
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
This is an umbrella, two-arm, multi-stage, phase II trial. The purpose of the trial in the early stage cohort is to determine if EBRT improves disease free survival (defined as the time from random assignment to disease…
- Conditions
- Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
- Trial name
- CAN-STAMP (NCT04159155)
- Testing
- External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto
Fallopian Tube Cancer, Ovarian Cancer
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00217555
- Testing
- gemcitabine hydrochloride, topotecan hydrochloride
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Cervical Cancer
Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer
The combination of radiation therapy or chemoradiation with Interstitial brachytherapy for advanced cervical cancer (pN+, FIGO-Stage II B - IV A is standard of therapy.
- Trial name
- NCT03249519
- Testing
- Radiation, brachytherapy, Cisplatin
- Where
- Germany
- Volunteers
- 999 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Ovarian Neoplasms, Ovarian Cancer
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
- Trial name
- OVERT-1 (NCT00610714)
- Testing
- AZD0530, Carboplatin, Paclitaxel
- Where
- 50 sites in Bulgaria, Canada and 10 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Polycystic Ovary Syndrome
Use of Osteopathic Principles for Nonpharmacologic, Therapeutic Interventions in Women With Polycystic Ovary Syndrome
The overall goals of this project are to assess the efficacy of non-pharmacological, complementary therapies to improve outcomes in the treatment of women with polycystic ovary syndrome (PCOS).
- Trial name
- NCT03383484
- Testing
- OMT, Yoga
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Diana Speelman, Ph.D.
Cervical Cancer
Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
To explore the efficacy and tolerance of adding toripalimab simultaneously and subsequently to concurrent platinum-based chemoradiotherapy in patients with locally advanced cervical cancer.
- Trial name
- NCT05084677
- Testing
- Toripalimab Combined With Concurrent Platinum-based Chemoradiotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Endometrial Cancer
Randomized Comparison Between Sentinel Lymph Node Biopsy and Lymph Node Dissection in Early Stage Endometrial Cancer
Through this clinical trial, the investigators aim to verify the usefulness and stability of sentinel lymph node mapping in endometrial cancer of clinical stage I-II.
- Trial name
- SELYE (NCT04845828)
- Testing
- Sentinel lymph node mapping, Routine lymph node dissection
- Where
- South Korea
- Volunteers
- 810 people
- Sponsor
- Asan Medical Center
Melanoma, Prostate Cancer
An Expanded Access Program for AM0010 (Pegilodecakin)
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- NCT03554434
- Testing
- AM0010
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.